<?xml version="1.0" encoding="UTF-8"?>
<p>The efficacy of nafamostat in patients with Covid-19 (RACONA study), is the subject of another ongoing clinical trial. The aim of the RACONA study is to test the hypothesis that nafamostat is useful in the treatment of COVID-19 lung damage. This hypothesis is justified by the fact that COVID-19 involves the activation of the coagulation cascade, pulmonary embolism, and bacterial superinfections (
 <xref rid="B73" ref-type="bibr">73</xref>).
</p>
